MACROGENICS INC
MGNXNASDAQTrading Snapshot
- Day Range
- $3.82 – $3.89
- 52-Week Range
- $1.29 – $5.08
- Volume
- $2.42B
- Avg Volume
- $2.26B
- Shares Outstanding
- 63.6M
- Next Earnings
- Dec 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $150M
- Last Q Revenue
- $33M
- P/E Ratio
- -17.5
- P/S Ratio
- 1.5x
- EPS (TTM)
- $-0.23
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.9%
Why Investors Own MGNX
- ✓High-growth profile — revenue up -9.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MACROGENICS INC
MGNX
StockOtter · stockotter.spaceAbout MACROGENICS INC
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced th
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
Positive risk/reward with MacroGenics trading at a discount to its $327 million cash position or $5.15/share. Differentiated pipeline includes antibody drug conjugates (ADC), T-cell engagers (TCE), and lorigerlimab, with
Bank of America Corp DE Buys 564,094 Shares of MacroGenics, Inc. $MGNX
Bank of America Corp DE increased its stake in shares of MacroGenics, Inc. (NASDAQ: MGNX) by 30.7% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,401,814 sh
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.57 per share a year ago.